# Louisiana Sheriffs Pension & Relief Fund v. Cardinal Health, Inc.

> District Court, S.D. Ohio · September 27, 2021

URL: https://www.frixlaw.com/law-library/cases/10378697

## Case

- **Court:** District Court, S.D. Ohio
- **Decided:** September 27, 2021
- **Opinion:** 100trialcourt
- **Cited by:** 0 later opinions in the Frix Law Library

## Citator (automated)

- No negative treatment found by the automated citator. That is not the same as a confirmation that the case is good law; read the citing cases.
- Full citator and citing cases: https://www.frixlaw.com/law-library/cases/10378697

## How later opinions describe it (automated extraction)

- stating “[e]ssentially, a plaintiff needs to allege a drop in stock price; establish a causal connection; and connect the alleged fraud with the ultimate disclosure and loss”
- stating “[e]ssentially, a plaintiff needs to allege a drop in stock price; establish a causal connection; and connect the alleged fraud with the ultimate disclosure and loss”

## Opinion text

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF OHIO
EASTERN DIVISION

LOUISIANA SHERIFFS’ PENSION &
RELIEF FUND, Individually and on
Behalf of All Others Similarly Situated,
Plaintiff, Case No. 2:19-cv-3347
JUDGE EDMUND A. SARGUS, JR.
v. Magistrate Judge Elizabeth P. Deavers

CARDINAL HEALTH, INC., et al.,

Defendants.

OPINION AND ORDER
This matter is before the Court on Defendants’ Motion to Dismiss the Consolidated
Amended Complaint. (ECF No. 31.) Plaintiff has filed a response in opposition (ECF No. 32)
and Defendants have replied (ECF No. 36). Plaintiff also filed a Motion to Strike Exhibits
Submitted with Defendants’ Motion to Dismiss (ECF No. 33), to which Defendants responded in
opposition (ECF No. 37), and Plaintiff replied (ECF No. 38). For the following reasons, the
Court DENIES Defendants’ Motion to Dismiss and DENIES AS MOOT Plaintiff’s Motion to
Strike.
I.
Plaintiff Louisiana Sheriffs’ Pension & Relief Fund brings this securities class action on
behalf of all purchasers of Cardinal Health common stock for the period March 2, 2015 and May
2, 2018, inclusive (the “Class Period”), alleging violations of §§ 10(b), 20(a) and 20A of the
Securities Exchange Act of 1934, 15 U.S.C. §§ 78j(b), 78t(a) and 78t-1, and United States
Securities and Exchange Commission (“SEC”) Rule 10b-5, 17 C.F.R. § 240.10b-5. (Am.
Compl. ¶ 1, ECF No. 28.) Plaintiff named as defendants Cardinal Health, Inc., (“Cardinal”), and
George S. Barrett, Donald M. Casey, Jr., Michael C. Kaufmann, Jorge M. Gomez, and David J.
Wilson who are current and former senior executives (collectively “Defendants”).
A. Amended Complaint
Cardinal is a global distributor of drugs and medical devices that is based in Dublin,

Ohio. (Am. Compl. ¶ 19, ECF No. 28.) Plaintiff alleges that, during the Class Period,
Defendants made material misrepresentations and omissions regarding Cardinal’s acquisition
and integration of Cordis Corporation (“Cordis”). Cordis is a manufacturer and global supplier
of cardiovascular and endovascular devices which Cardinal purchased from Johnson & Johnson
in 2015 for $1.9 billion. (Id. ¶¶ 2, 20.)
The Cordis acquisition is alleged to have been a key part of Cardinal’s business strategy
to bolster stagnated margins in its medical device segment and to offset declining revenues in
Cardinal’s pharmaceutical business. (Id. ¶¶ 19–24.) This acquisition is alleged to have been the
largest in Cardinal’s 40-year history. (Id. ¶ 23.) One of Cardinal’s top executives, Don Casey,
was a former Johnson & Johnson executive who oversaw the global cardiovascular group.

Plaintiff alleges that Mr. Casey assured analysts and investors that Defendants had a deep
understanding of the business throughout the acquisition period. (Id.)
Defendants allegedly misled investors by repeatedly assuring the market that they were
transforming Cordis’ business with Cardinal’s inventory management technology and supply
chain expertise, which would result in significant operating efficiencies and earnings accretion
for investors. Plaintiff alleges that Defendants claimed that Cardinal and Cordis were able to
offer reliable, trackable inventory and logistics and deep analytic capabilities, and that Cardinal
was implementing its radio-frequency identification (“RFID”) technology at Cordis to eliminate
or reduce expired and lost inventory and lower managed inventory levels. (Id. ¶¶ 32–33, 37, 41–
45, 58.)
Defendants also allegedly told investors that they expected the Cordis acquisition to be
more than $0.20 per share accretive in fiscal year (“FY”) 2017, the first full year after the

acquisition, and that Cardinal would achieve at least $100 million in annual synergies by the end
of FY 2018, all as a result of their purported transformation of Cordis. (Id. ¶¶ 31-32, 34, 36, 41,
43, 48, 53, 55, 65.) The Amended Complaint throughout alleges that Defendants continually
assured investors that Cardinal’s integration of Cordis was on track, on plan and going very well,
that Cordis’ business was performing very well and as expected, and that Cordis was generating
top-line revenue growth. (Id. ¶¶ 43, 46–47, 49–52, 54, 56– 57, 59– 61, 75– 77, 80– 82.)
Plaintiff alleges that Defendants’ statements about Cardinal’s Cordis acquisition,
integration, and inventory were false and misleading. Plaintiff specifies that from the time the
Cordis acquisition was announced, and throughout the Class Period, Defendants allegedly
concealed debilitating inventory management and tracking problems plaguing Cordis, failed to

disclose that Cordis was carrying $200 to $300 million in excess, obsolete, expired, missing and
unaccounted-for inventory in its warehouses in El Paso, Colombia, Brazil, Mississippi, Belgium
and Japan, which was not being reflected in Cardinal’s earnings throughout the Class Period.
(Id. ¶ 67(a)(ii).) Plaintiff further alleges that Cardinal was incurring significant cost overruns in
setting up a global supply chain for Cordis, and that Cordis’ most popular products were on back
order and therefore could not be sold when needed. (Id. ¶ 67.) Plaintiff avers that Cordis
products had short shelf lives of one to two years, causing the excess inventory to expire before it
could be utilized. (Id. ¶¶ 67, 71, 83.)
Plaintiff additionally alleges that Defendants’ inability to track inventory was further
exacerbated when, in July of 2017, Cordis’ iTrak inventory management system completely shut
down by the amount of Cordis’ inventory outside the United States. (Id. ¶¶ 71, 83(a)). As a
result, Defendants had no visibility of Cordis worldwide inventories from July 2017 and

continuing for the next year. Id. Internally at Cardinal, Plaintiff avers, this was called the “Dark
Period” or the “Blackout Period.” (Id.)
The Amended Complaint continues, alleging that on “May 3, 2018, Cardinal shocked
investors and analysts by announcing before the markets opened that Cardinal’s GAAP
[Generally Accepted Accounting Principles] diluted EPS [Earnings Per Share] for 3Q [third
quarter] FY 2018 decreased 33% to $0.81 because of higher than expected Cordis inventory
reserves and that the Cordis business was a disaster and would not see profitable growth until the
end of FY 2019.” (Id. ¶ 5.) “On the news that Cordis’ inventory and sales issues negatively
affected Cardinal’s earnings, Cardinal’s stock price fell over 21% on May 3 on huge trading
volume of 15,594,300 shares – by far the biggest trading day since the beginning of the Class

Period.” (Id. ¶ 89.)
Plaintiff avers that, before this stock fall in May 2018, Defendant David Wilson, Cordis’
Worldwide President, left abruptly in August 2017; three months later, in November 2017,
Cardinal announced that defendant George Barrett would resign as Chief Executive Officer
(“CEO”) effective January 2018; and in early February 2018, defendant Don Casey, CEO of
Cardinal’s Medical Segment and the chief advocate of the Cordis acquisition, left abruptly. (Id.
¶¶ 14, 72, 78, 111.) Plaintiff alleges “[t]wo of these insiders sold over 1.3 million shares of
Cardinal stock at artificially inflated prices, reaping over $113 million in proceeds before leaving
the Company.” (Id. ¶ 4.)
Plaintiff continues, alleging that “after the Class Period in August 2018, Cardinal
announced a $1.4 billion non-cash goodwill impairment charge, primarily driven by ‘inventory
and cost challenges within [the] Cordis business.’” (Id. ¶ 91, Ex. 102, Aug. 22, 2018 Form 10-K
at 16.) Plaintiff further alleges that, “the $1.4 billion write down negatively impacted Cardinal’s

FY 2018 operating profits, which declined 94% from $2.12 billion (2017) to $126 million
(2018). (Id. ¶¶ 91, 129.) Plaintiff summarizes that Cardinal’s $1.4 billion non-cash goodwill
write-down erased 100% of the goodwill recorded for the Cordis acquisition, representing nearly
74% of the $1.9 billion purchase price that Cardinal paid to acquire Cordis on October 4, 2015.
(Id. ¶ 129.) Plaintiff concludes that the $1.4 billion write off in less than three years is explained
in the allegations in the Amended Complaint as deception of the investors from the start in
violation of the federal securities laws.
B. Claims for Relief
There are three claims for relief asserted in the Amended Complaint on behalf of a class
of investors. In the first, Plaintiff alleges that Defendants violated § 10(b) of the Securities

Exchange Act and SEC Rule 10b-5, by making false and misleading statements about the
acquisition, integration, and performance of Cordis and issued false public financial statements
for Cardinal during the Class Period—March 2, 2015 to May 2, 2018. (Am. Compl. ¶¶ 149–53,
ECF No. 28.) In the second claim, Plaintiff alleges that the individual defendants are persons
who controlled Cardinal under § 20(a) of the Securities Exchange Act, and therefore are
secondarily liable for Cardinal’s alleged violations of § 10(b) and Rule 10b-5. (Id. ¶¶ 154–157.)
The third claim is brought against Defendant Barrett under § 20A of the 1934 Act because he
allegedly violated the Securities Exchange Act by selling Cardinal stock during the Class Period
while in possession of material, non-public information about the company. (Id. ¶¶ 158–67.)
II.
Defendants have moved for dismissal of all three causes of action for failure to state a
claim upon which relief can be granted. (Defs’ Mot. to Dismiss (“Defs.’ Mot.”), ECF No. 31.)
That motion is ripe for review. (ECF Nos. 32, 26.)

A. Federal Rule of Civil Procedure 12(b)(6)

To survive a motion to dismiss under Rule 12(b)(6) of the Federal Rules of Civil
Procedure, “a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim
to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 677–78 (2009) (quoting
Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). “A claim has facial plausibility when the
plaintiff pleads factual content that allows the court to draw the reasonable inference that the
defendant is liable for the misconduct alleged.” Id. Furthermore, “[a]lthough for purposes of a
motion to dismiss [a court] must take all the factual allegations in the complaint as true, [it][is]
not bound to accept as true a legal conclusion couched as a factual allegation.” Id. at 677–79
(quoting Twombly, 550 U.S. at 55) (internal quotations omitted). This standard “does not impose
a probability requirement at the pleading stage; it simply calls for enough fact to raise a
reasonable expectation that discovery will reveal evidence of illegal [conduct].” Ohio Pub.
Emps. Ret. Sys. v. Fed. Home Loan Mortg. Corp., 830 F.3d 376, 383 (6th Cir. 2016) (quoting
Twombly, 550 U.S. at 556). When considering a motion to dismiss under Rule 12(b)(6), a court
“considers the complaint in its entirety, as well as . . . documents incorporated into the
complaint by reference, and matters of which a court may take judicial notice.” Id. (citing
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308, 322 (2007)).
B. Heightened Pleading Requirements for Private Securities Fraud Claims

Security fraud actions brought pursuant to the Securities and Exchange Act are subject to
the heightened pleading standards of Federal Rule of Civil Procedure 9(b). Id. Under Rule 9(b),
when alleging fraud, “a party must state with particularity the circumstances constituting” the
fraud. Fed. R. Civ. P. 9(b). This means that a complaint must “(1) specify the statements that
the plaintiff contends were fraudulent, (2) identify the speaker, (3) state where and when the
statements were made, and (4) explain why the statements were fraudulent.” Doshi v. Gen.
Cable Corp., 386 F. Supp. 3d 815, 826 (E.D. Ky. 2019) (citing Dougherty v. Esperion
Therapeutics, Inc., 905 F.3d 971, 978 (6th Cir. 2018)).
Moreover, the Private Securities Litigation Reform Act of 1995 (“PSLRA”) imposes
additional pleading requirements. Id. A plaintiff must “specify each statement alleged to have
been misleading” along with “the reason or reasons why the statement is misleading” and,
finally, “state with particularity facts giving rise to a strong inference that the defendant acted

with the required state of mind.” Ohio Pub. Emps. Ret. Sys., 830 F.3d at 384 (citing 15 U.S.C. §
78u–4(b)(1)(B), (b)(2)(A)).
III.
Defendants argue that they are entitled to dismissal of all claims in the Amended
Complaint because Plaintiff does not adequately plead securities fraud under either (A) § 10(b) if
the Securities Exchange Act, or (B) § 20(a) and § 20A of the Securities Exchange Act. (Am.
Compl. ¶ 13, ECF No. 28.)
A. Claims Under § 10(b) and Rule 10b-5
Section 10(b) of the Securities Exchange Act “makes it unlawful for any person to ‘use or
employ, in connection with the purchase or sale of any security . . . any manipulative or
deceptive device or contrivance in contravention of such rules and regulations as the
Commission may prescribe as necessary or appropriate in the public interest or for the protection
of investors.’” Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27, 37 (2011) (citing 15 U.S.C. §
78j(b)). SEC Rule 10b-5 implements § 10(b), specifying it as unlawful to “make any untrue

statement of a material fact or to omit to state a material fact necessary in order to make the
statements made, in the light of the circumstances under which they were made, not misleading.”
Id. (citing 17 C.F.R. § 240.10b-5(b)).
To succeed on a claim under § 10(b) of the Securities Exchange Act and SEC Rule 10b-
5, Plaintiff must prove six elements: “(1) a material misrepresentation or omission by the
defendant; (2) scienter; (3) a connection between the misrepresentation or omission and the
purchase or sale of a security; (4) reliance upon the misrepresentation or omission; (5) economic
loss; and (6) loss causation.” Id. at 37–38 (quoting Stoneridge Investment Partners, LLC v.
Scientific–Atlanta, Inc., 552 U.S. 148, 157 (2008)).
Defendants only challenge the pleading adequacy of the first, second, and sixth

elements—materiality, scienter, and loss causation. (Defs.’ Mot. at 14.) Specifically, they argue
that the Amended Complaint: (1) does not sufficiently allege that “the statements by the
company or its executives regarding Cordis, or the company’s financial statements, contained
any material misrepresentations or omissions”; (2) does “not come close to pleading with
particularity that the company or any of its executives acted with scienter”; and (3) does not
“adequately allege loss causation . . . in connection with the company’s alleged issuance of false
financial statements” (Id.) The Court addresses each of these in turn.
1. Material Misrepresentations or Omissions

To prevail on a § 10(b) and Rule 10b-5 claim, a plaintiff must show that the alleged
statements “were misleading as to a material fact.” Basic Inc. v. Levinson, 485 U.S. 224, 238
(1988). “It is not enough that a statement is false or incomplete, if the misrepresented fact is
otherwise insignificant.” Id. Whether a statement or omission is material depends on “the
significance the reasonable investor would place on the withheld or misrepresented information.”
Helwig v. Vencor, Inc., 251 F.3d 540, 555 (6th Cir. 2001), abrogated on other grounds by
Tellabs, 551 U.S. 308, (citing Basic, 485 U.S. at 238)).
An omission is material if there is a “substantial likelihood that the” false statement “or
disclosure of the omitted fact would have been viewed by the reasonable investor as having
significantly altered the ‘total mix’ of information made available.” Basic, 485 U.S. at 231–32
(citing TSC Industries, Inc. v. Northway, Inc., 426 U.S. 438, 449 (1976)). Materiality is an
“inherently fact-specific” inquiry. Basic, 485 U.S. at 236. As such, a court may only determine

that a statement or omission is not material as a matter of law “if the alleged misrepresentations
or omissions are so obviously unimportant to a” reasonable investor “that reasonable minds
cannot differ on the question of materiality.” In re Cardinal Health Inc. Sec. Litigations, 426 F.
Supp. 2d 688, 747 (S.D. Ohio 2006) (citing, inter alia, citing Shapiro v. UJB Fin. Corp., 964
F.2d 272, 281 n. 11 (3d Cir. 1992)).
Importantly, § 10(b) and Rule 10b-5 do not “create an affirmative duty to disclose any
and all material information.” Matrixx Initiatives, 563 U.S. at 44. An affirmative duty to
disclose may arise when a company has made “an inaccurate, incomplete or misleading prior
disclosure.” City of Monroe Emps. Ret. Sys. v. Bridgestone Corp., 399 F.3d 651, 669 (6th Cir.
2005) (citing In re Digital Island Sec. Litig., 357 F.3d 322, 329 n. 10 (3d Cir. 2004)). Otherwise,
disclosure is required only when necessary “to make . . . statements made, in light of the
circumstances under which they were made, not misleading.” Id. (citing 17 C.F.R. § 240.10b-
5(b))
Defendants argue that the statements in Amended Complaint are immaterial as a matter

of law for three reasons: (a) most of the statements are “vague, soft, puffing statements” or
“generalized statements of optimism that are not capable of objective verification,” (b) most of
the statements are forward-looking that fall within the PSLRA’s safe harbor, and (c) statements
disclosing the past financial performance of Cardinal and Cordis are not materially misleading
because the “disclosure of accurate historical data does not become misleading even if less
favorable results might be predictable by the company in the future.” (Defs.’ Mot. at 15, 17, 19,
ECF No. 31.)
a. Vague, Soft, Puffing Statements
In considering materiality in securities regulation, the Sixth Circuit has distinguished
“hard” information and “soft” information. Id. (citing In re Sofamor Danek Grp., Inc., 123 F.3d

394, 401 (6th Cir. 1997)). “Hard information” is “typically historical information or other factual
information that is objectively verifiable.” Id. Hard information, publicly disclosed, is
actionable if it is misleading and material. Id. In contrast, “soft information”—sometimes called
“puffery”—includes “predictions and matters of opinions” not capable of objective verification.
Id. (citing Sofamor Danek Grp., 123 F.3d at 401). “[V]ague, soft, puffing statements or obvious
hyperbole upon which a reasonably investor would not rely” are immaterial as a matter of law.
In re Ford Motor Co. Sec. Litig., 381 F.3d 563, 570 (6th Cir. 2004) (citation omitted). The
“context in which a statement is made is essential in determining whether a statement is puffery.”
In re Huffy Corp. Sec. Litig., 577 F. Supp. 2d 968, 1007 (S.D. Ohio 2008); see also City of
Monroe, 399 F.3d at 672 (quoting Casella v. Webb, 883 F.2d 805, 808 (9th Cir. 1989) (“What
might be innocuous ‘puffery’ or mere statement of opinion standing alone may be actionable as
an integral part of a representation of material fact when used to emphasize and induce reliance
upon such a representation.”)).

In In re Ford Motor Co. Securities Litigation, the Sixth Circuit explained that puffery is
the “kind of rosy affirmation commonly heard from corporate managers and numbingly familiar
to the marketplace—loosely optimistic statements that are so vague, so lacking in specificity, or
so clearly constituting the opinions of the speaker, that no reasonable investor could find them
important to the total mix of information available.” 381 F.3d 563, 570–71 (6th Cir. 2004). In
that case the defendant Ford made the following statements:
1) “[A]t Ford quality comes first.”; 2) “We aim to be the quality leader”; 3) “Ford
has its best quality ever”; 4) Ford is “taking across-the-board actions to improve ...
[its] quality.”; 5) Ford has made “quality a top priority”; 6) “Ford is a worldwide
leader in automotive safety”; 7) Ford has made “quality a top priority”; 8) Ford is
“designing safety into . . . [its] cars and trucks” because it wants its “customers to
feel safe and secure in their vehicles at all times”; 9) Ford “want[s] to make
customers' lives ... safer”; 10) Ford has “dedicated . . . [itself] to finding even better
ways of delivering ... safer vehicles to [the] consumer”; 11) Ford “want[s] to be
clear leaders in corporate citizenship”; 12) Ford's “greatest asset is the trust and
confidence . . . [it] has earned from . . . [its] customers”; 13) Ford “is going to lead
in corporate social responsibility.”

Id. at 570 (alterations in original). These statements, the court said, were “mere corporate
puffery or hyperbole that a reasonable investor would not view as significantly changing the
general gist of available information.” Id.
In the case sub judice, Defendants argue that “most, if not all, of the statements the
complaint alleges to be false or misleading are immaterial” because the statements are puffery.
(Def. Mot. at 15, ECF No. 31) (citing Am. Compl. ¶¶ 33, 37–38, 41–47, 49–54, 56–59, 61, 65,
73–74, 76–77, 80–82, ECF No. 28). These statements, however, do not fall within the “certain
kind” of statements the Sixth Circuit find constitutes mere corporate puffery or hyperbole that a
reasonable investor would not view as significantly changing the general gist of available
information. By way of example, the following paragraphs are the types of statements
Defendant maintain constitute puffery.

• March 2, 2015, during the conference call, a defendant told investors that Cordis will
“leverage [Cardinal’s] highly efficient delivery model and investments we have
made in RFID technology by virtue of our WaveMark acquisition.” He explained
that “this shared platform connects manufacturers and providers with supply chain
visibility and analytics” and “reduc[es] expired and lost products, lowering managed
inventory levels and decreasing holding costs.” He concluded, “[a]ll this adds up to
significant potential operating efficiencies . . . [and Cordis would] benefit from our
efficient shared distribution system to drive significant supply chain savings.” (Am.
Compl. ¶ 33.)

• March 3, 2015, a defendant stated at a conference:
We think there is a different way to bring value to the market around those products.
It’s not just a product and account of those products. It’s the way that they are
managed in the cath lab, it’s how much inventory you are carrying, it’s whether or
not, you can tag them to prevent leakage or loss of a product, prevent a product from
expiring.

So they are all kinds of supply chain tools built around . . . this that could
change the paradigm, and it’s actually largely what we see. . . . So we see this as a
growth opportunity actually in this area. . . . For us, we see a great opportunity and
then combining it with our supply chain expertise. (¶ 37.)

• April 10, 2015, article: “By leveraging its RFID-enabled supply chain capabilities,
[Cardinal] believes it can continue to see growth and get more mileage from mature,
but well-respected products such [as] those offered by Cordis.” On an April 30, 2015
Cardinal earnings conference call for 3Q 2015, Kaufmann confirmed “in FY17, the
first full year post-close, we expect the transaction to be greater than $0.20 accretive
and increasingly accretive thereafter. We still expect operational synergies of at least
$100 million annually by the time we exit FY18.” (¶ 41.)

• October 31, 2016, conference: “The integration of Cordis has proved to be an
excellent example of how we can bring together best practices across borders. We
have seen over this past year, that taking the time to do things right is essential to
best serve our customers. We have also seen growth in some important markets
including Europe, where we believe that taking an integrated cohesive approach to
our customers will position us for measurable growth over the long term. (¶ 56.)
• On September 11, 2017, conference call: [F]rom a top line, Cordis is performing very
close to where we expected it to be. And that has been one of the absolute most
important things for us because if you lose the sales, it’s incredibly hard to get them
back. And so while we’re a little bit behind where we expected in some markets and
ahead in other markets, overall, the overall sales volume of Cordis is about where we
expected it to be. (¶ 74.)
In contrast to the statements made in the In re Ford Motor Co. Securities Litigation case,
the above statements made by Defendants, and those not specifically quoted, are not the “kind of
rosy affirmation commonly heard from corporate managers” that are “so vague, so lacking in
specificity, or so clearly constituting the opinions of the speaker, that no reasonable investor
could find them important to the total mix of information available.” 381 F.3d at 570–71. On
the investor conference calls and in publications from the beginning of the Class Period to early
February 2017, Plaintiff’s allegations show that Defendants spoke about how Cordis would
benefit from Cardinal’s inventory management technology and supply chain expertise, and how
that would translate into cost synergies and earnings accretion for Cardinal, all in the context of
discussing the acquisition and integration of Cordis. (Am. Compl. ¶¶ 32–33, 33, 37, 41– 45, 58,
ECF No. 28.)
Additionally, in context, which “is essential in determining whether a statement is
puffery,” the statements appear to be made to reassure investors about the success of the
acquisition and integration of Cordis, which was of importance to investors because Cardinal’s
entry into manufacturing interventional cardiovascular products represented a significant
departure from the low-tech and low-margin medical supplies Cardinal had traditionally sold.
Huffy, 577 F. Supp. 2d at 1007. Unlike Cardinal’s other products, Cordis’ heart stints and
catheters had strict expiration dates that had to be closely monitored for quality and regulatory
standards. (Id. ¶¶ 30, 67(a).) Moreover, the acquisition greatly expanded Cardinal’s geographic
footprint; Cordis lacked international supply chain and distribution capabilities as it was a
Johnson & Johnson portfolio consisting of only intellectual property, inventory and a sales force.
Plaintiff alleges that managing Cordis’ consigned and warehouse inventory posed significant
operational challenges for Cardinal. (Id. ¶¶ 30, 67(c).) Thus, Cardinal’s implementation of an
effective inventory management system and supply chain was important to the total mix of

information available regarding the success of the integration and Cardinal’s accretive
expectations for Cordis.
In this context, it would have been material to reasonable investors to know that
Defendants were unable to accurately track how much of Cordis’ consigned and warehouse
inventory actually existed, how much of it was excess and obsolete or about to expire, how much
of it was missing or unaccounted-for, and where it was located around the world. (Id. ¶ 67.)
Given the central importance of inventory management to the Cordis business, it was also
material to investors to know that Cordis was actually carrying $200 to $300 million in excess,
obsolete, expired, missing and unaccounted-for inventory in 2015 through 2017, that Cardinal
had been forced to manually count consignment inventory in North America, Europe, the Middle

East and Asia, and that Cardinal could not forecast demand for Cordis products. (Id.) Instead,
Plaintiff alleges that the investors were misled about Cordis and kept in the dark as to these
adverse factors. The Court finds that the statements at issue here do not constitute puffery and
instead were capable of verification. That is, they are “assertion[s] of a relationship between
data and a conclusion, one that a finder of fact could test against record evidence.” See City of
Monroe Employees Ret. System v. Bridgestone Corp., 399 F.3d 651, 674 (6th Cir. 2005).
b. Safe Harbor
The PSLRA carves a safe harbor for forward-looking statements by executive officers that
were “accompanied by meaningful cautionary statements identifying important factors that could
cause actual results to differ materially from those in the forward-looking statement” or were
“immaterial.” 15 U.S.C. § 78u–5(c)(1)(A); see also 15 U.S.C. § 78u–5(i)(1) (defining “forward-
looking statement”); Dougherty v. Esperion Therapeutics, Inc., 905 F.3d 971, 983 (6th Cir. 2018).
Defendants focus only on the first portion of the safe harbor provision – that the statements were

forward looking and were accompanied by meaningful cautionary language.
Defendants divide the allegedly forward looking statements into two groups: (i) their
statements from March 2015 to August 2016 “regarding the earnings accretion and synergies it
expected to achieve from the Cordis acquisition,” and, (ii) their statements made about “general
expectations or outlook” for Cordis in filings or conference calls made throughout the Class
Period. (Defs.’ Mot. at 17–19.)
i. Statements in 2015 and 2016 about earnings accretion and
synergies

After announcing the Cordis acquisition in March 2015, Defendants made the following
statements about the “accretion” and “synergies” it expected Cordis to achieve in fiscal years
2017 and 2018:
• March 2, 2015. Cardinal Health’s form 8-K announced the Cordis acquisition and
stated that “Fiscal 2017, first full post-close year, accretion [from Cordis] is
expected to be greater than $0.20 in non-GAAP diluted earnings per share from
continuing operations; increasingly accretive thereafter.” (Am. Compl. ¶ 31.)

• March 2, 2015. Defendants presented slides to investors regarding the Cordis
acquisition which stated that the acquisition was expected to be “significantly
accretive to [Cardinal’s] Medical Segment margin Rates,” expected to be “greater
than $0.20 in non-GAAP EPS accretion in FY 17” and “increasingly accretive
thereafter,” with “[a]nnual synergies of at least $100M expected exiting FY18.”
(Id. ¶ 32.)

Defendants Barrett and Kauffman reiterated that Defendants expected “the
transaction to be greater than $0.20 accretive in fiscal 2017, which is the first full
year post close, and we expect this to be increasingly accretive thereafter. . . . We
expect operational synergies of at least $100 million annually to be realized by the
time we exit our fiscal 2018.” (Id. ¶ 34.)
• March 3, 2015. Defendant Barrett attended an investor health care conference and
repeated that the “economics of [the Cordis] deal are extremely attractive. We
expect it to be more than $0.20 accretive in fiscal FY17. We expect by the end of
2018 to achieve about $100 million or more of synergies. And we think this is really
important driver for us.” (Id. ¶ 36.)

• April 30, 2015. Defendant Kauffman repeated the $.020 accretion and $100
million “operational synergies” expectations regarding Cordis on a conference call
for 3Q 2015. (Id. ¶ 41.)

• February 1, 2016. On an earnings conference call for 2Q 2016, Defendant
Kauffman reported that “in FY17 we still expect the transaction to be greater than
$0.20 accretive, and increasingly accretive thereafter. We are also working towards
achieving the $100 million of annual synergies as we exit our FY18.” (Id. ¶ 48.)

• August 2, 2016. Defendant Kauffman stated on a conference call for 4Q 2016 that
Cardinal lowered Cordis’ expected fiscal year 2017 accretion in non-GAAP diluted
earnings from $0.20 to $0.15 per share, “largely due to currency impacts, as well
as some increased SG&A investments compared to our original business case.”
Defendant Kaufmann also told investors that the Company was still expecting
“double-digit segment . . . growth and margin . . . expansion” from the Medical
Segment due to “expect[ed] great performance from Cordis.” (Id. ¶ 55.)

Plaintiff argues that even if these statements are forward-looking within the meaning of
the PSLRA, they do not fall within the safe harbor protection because the cautionary language
used by Defendants was not “meaningful.” (Pl.’s Resp. at 22–24.) This Court agrees.
To qualify as “meaningful,” a cautionary statement must “convey substantive
information about factors that realistically could cause results to differ materially from those
projected in the forward-looking statements, such as, for example, information about the issuer’s
business.” In re Humana, Inc. Sec. Litig., No. CIVA 308CV-00162-JHM, 2009 WL 1767193, at
*12 (W.D. Ky. June 23, 2009) (quoting Helwig, 251 F.3d at 558–59) (internal quotations
omitted). Boilerplate warnings are not sufficient. Id.; but see In re Kindred Healthcare, Inc.
Sec. Litig., 299 F. Supp. 2d 724, 739 (W.D. Ky. 2004) (“Simply because language is repeated
does not classify it as ‘boilerplate.’”). “‘[C]autionary statements must be substantive and tailored
to the specific future projections, estimates, or opinions . . . which the plaintiffs challenge.” Id.
(citing Helwig, 251 F.3d at 559). However, the “PSLRA does not require companies to warn of
‘the particular factor that ultimately causes the forward-looking statement not to come true’ in
order to receive protection under the safe harbor provision.” Id. (quoting Harris v. Ivax Corp.,

182 F.3d 799, 807 (11th Cir. 1999)). When an investor “has been warned of risks of a
significance similar to that actually realized, she is sufficiently on notice of the danger of the
investment to make an intelligent decision about it according to her own preferences for risk and
reward.” Helwig, 251 F.3d at 559 (citing Harris, 182 F.3d at 807).
The cautionary statements Defendants posit are meaningful provide that the Cordis
acquisition is “subject to risks and uncertainties that could cause actual results to differ
materially from those projected[.]” (Bloomfield Decl., Ex 5, ECF No. 29.) The Form 8-K was
accompanied by a press release that also listed as one of several future uncertainties as the ability
to “integrate the acquired business into Cardinal’s operations, if the acquisition is completed;
[and] the ability to achieve the expected synergies as well as accretion in earnings[.]” (Id.)

The oral statements alleged at ¶¶ 34, 36, 41, 48, and 55 discussing Cordis’ expected
future accretion and synergies were also accompanied by cautionary language. At the
conference call on March 2, a Cardinal executive warned that Defendants would be making
“forward-looking statements” that “are subject to risks and uncertainties that could cause actual
results to differ materially”; the executive referred listeners “to [Cardinal’s] SEC filings and the
forward-looking statements slides at the beginning of presentation found on the Investor page of
the Cardinal website. (Id., Ex. 6.) The April 30 conference call contained the same cautionary
statement and referred listeners the “forward-looking statements slide” of the presentation. That
slide listed several specific future uncertainties, including “the ability to successfully complete
the acquisition of Cordis on a timely basis and if completed to achieve the anticipated results
from the Cordis acquisition[.]” (Id., Ex. 15.) Defendants made similar cautionary statements at
the beginning of the February 1, 2016 and August 2, 2016 conference calls.
The cautionary language Defendants highlight regarding the expected accretion and

synergies from the Cordis acquisition was a general warning to investors that results could differ
materially from those projected anticipated or implied. To be meaningful, the cautionary
language “‘must be substantive and tailored to the specific future projections, estimates or
opinions . . . which the plaintiffs challenge.’” Helwig, 251 F.3d at 559. For example, in In re
Humana, Inc. Securities Litigation, the court found the following “cautionary statements are not
vague or blanket disclaimers, but instead are substantive, extensive, and tailored to the future-
looking statements they reference.”:
Our business depends significantly on effective information systems and the
integrity and timeliness of the data we use to run our business. . . . As a result of
our past and on-going acquisition activities, we have acquired additional
information systems. We have been taking steps to reduce the number of systems
we operate, have upgraded and expanded our information systems capabilities, and
are gradually migrating existing business to fewer systems. Our information
systems require an ongoing commitment of significant resources to maintain,
protect and enhance existing systems and develop new systems to keep pace with
continuing changes in information processing technology, evolving industry and
regulatory standards, and changing customer preferences. If the information we rely
upon to run our business was found to be inaccurate or unreliable or if we fail to
maintain effectively our information systems and data integrity, we could have
operational disruptions, have problems in determining medical cost estimates and
establishing appropriate pricing, have customer and physician and other health
care provider disputes, have regulatory or other legal problems, have increases in
operating expenses, lose existing customers, have difficulty attracting new
customers, or suffer other adverse consequences.

(Humana 2007 Form 10–K at 18; Humana 2006 Form 10–K at 18.); see also id. at
19 (“Failure to adequately protect and maintain the integrity of our information
systems and data may result in a material adverse effect on our financial positions,
results in operations and cash flows.”)
Humana's cautionary language also warned explicitly that its expected
earnings were susceptible to risks associated not only with inaccuracies in
Humana's data and information systems, but also in the design and pricing of its
products. Humana specifically warned investors that failure by the Company to
“design and price our products properly and competitively” could cause its
profitability to decline. (Humana Form 10–Q (October 29, 2007) at 26.) See also
Humana 2006 Form 10–K at 17 (“[I]f we lose accounts with favorable medical cost
experience while retaining or increasing membership in accounts with unfavorable
medical cost experience, our business and results of operations could be materially
adversely affected.”)

Similarly, Humana also informed investors of the manner in which it
calculated future benefit and medical claims, the numerous risks associated with
its estimation of the costs of the claims and other expenses, and the potential impact
of these items on the profitability of the company. (Humana 2007 Form 10–K at
16) (“We estimate the costs of our future benefit claims and other expenses using
actuarial methods and assumptions based upon claim payment patterns, medical
inflation, historical developments, including claim inventory levels and claim
receipt patterns, and other relevant factors.”); see also Humana 2006 Form 10–K at
16). Humana expressly identified numerous factors that could potentially “cause
actual health care costs to exceed what was estimated and used to set [Humana's]
premiums,” including “increased use of medical facilities and services, including
prescription drugs; . . . our membership mix; variances in actual versus estimated
levels of cost associated with new products, benefits or lines of business, product
changes or benefit level changes.” Id.

The cautionary language used gave investors particular information about
the effect that utilization of inaccurate benefit claims information and the effect that
possible variances in actual verses estimated levels of cost associated with new
products, benefits or benefit level changes could have on Humana's financial health.
Humana's cautionary statements provided investors company and industry specific-
risks and described their impact on Humana's financial results. This cautionary
language warned of risks similar to those that ultimately led Humana to revise its
earnings guidance downward on March 12, 2008.

In re Humana, Inc. Securities Litig., CIVA 308CV-00162-JHM, 2009 WL 1767193, at *13–14
(W.D. Ky. June 23, 2009) (emphasis added). As can be seen by this quote, unlike Cardinal’s
language, Humana’s cautionary language was substantive, extensive, and tailored to the future-
looking statements.
Here, Plaintiff persuasively argues that:
To be substantive and tailored here, Defendants’ March 2, 2015 cautionary
language would have had to include that Cordis: (1) had inadequate inventory
controls and no properly functioning inventory management system in place when
the acquisition was announced; (2) was unable to accurately track consigned and
warehouse inventory or forecast demand; and (3) Cordis was experiencing
debilitating problems with product backorders and was manufacturing excess
products, which were subject to strict expiration dates. ¶67(a)-(b). Defendants’
cautionary language thereafter would have had to continue to warn of these risks
and that Cordis was carrying at least $200-$300 million in excess, obsolete and
expired inventory and that by summer 2017 Defendants had lost all visibility into
Cordis’ ex-U.S. inventories. ¶¶67(a), 71, 83(a). But it did not.

The inadequacy of Defendants’ cautionary language is demonstrated by the fact
that, when investors learned the truth about the negative impact Cordis was having
on Cardinal’s earnings, they were surprised and disappointed by Defendants’ “lack
of visibility, lack of good inventory controls, and lack of understanding of the full
required investment [for Cordis].” ¶90(b).

(Pl. Mem. in Opp. at 22–23.)
While it is unnecessary for the Court to determine what a meaningful cautionary
statement would be in the context of the Cordis acquisition, what Defendants offer as cautionary
statements do not convey substantive information about factors that realistically could cause the
results to differ materially from those projected in the forward-looking statements. Accordingly,
these proposed forward-looking statements do not qualify for protection of the PSLRA’s safe
harbor.
ii. Statements about general expectations or outlook
Defendants also argue that all statements made throughout the Class Period “regarding
general expectations or outlook for Cordis in filings and on investor or analyst conference calls”
qualify for the PSLRA safe harbor. (Defs.’ Mot. at 18) (citing Am. Compl. ¶¶ 32–34, 36-38, 41–
43, 45–52, 54–61, 63, 65, 68–69, 73–77, 79, 80–82, ECF No. 28).) Plaintiff responds that these
statements were not forward-looking and were instead “statements of present or historic fact[,]”
making them ineligible for the PSLRA safe harbor. (Pl.’s Resp. at 21 (citing Willis v. Big Lots,
Inc., No. 2:12-cv-604, 2016 WL 8199124, at *12 (S.D. Ohio Jan. 21, 2016).) This Court agrees.
A statement is not considered “forward-looking” under the PSLRA safe harbor if it
relates to “past or current, rather than future, performance[.]” Fidel v. AK Steel Holding Corp.,

No. C-1-00-320, 2002 WL 31545952, at *19 (S.D. Ohio Sept. 19, 2002); see also Miller v.
Champion Enterprises Inc., 346 F.3d 660, 678 (6th Cir. 2003) (A “statement of present or
historical fact . . . is not subject to the safe harbor provision of the PSLRA.”). However, what
might seem like a statement of present or historical fact qualifies as a forward-looking statement
if it is a “statement of the assumptions underlying or relating to any” forward-looking statement.
15 U.S.C. § 78u-5(i)(1)(D).
The “critical inquiry in determining whether a statement is forward-looking is whether its
veracity can be determined at the time the statement is made.” Dougherty v. Esperion
Therapeutics, Inc., 905 F.3d 971, 983 (6th Cir. 2018). “If so, then the statement is not forward-
looking”—even if the statement pertains to a future event. Id. (citing Julianello v. K-V

Pharmaceutical Co., 791 F.3d 915, 921 (8th Cir. 2015)). As the court in Dougherty explained,
“take for instance a man’s statement to his friend, ‘My girlfriend has agreed to marry me.’ That
is not a forward-looking statement. Rather, it is a backward-looking statement concerning a
future event.” Id.
Applying the foregoing standards, the challenged statements about the “general
expectations or outlook for Cordis” are statements of present or historical fact that could be
verified at the time they were made, and thus are not forward-looking:
• January 12, 2016. Defendant Kaufmann told investors on a J.P. Morgan
conference call that “I just wanted to let you know right now everything’s going as
planned on Cordis . . . for right now, I just want you to know from everything we
see things are going as planned and as expected.” Defendant Barrettt confirmed
that “the integration has gone well.” (Am. Compl. ¶ 46.)

• February 1, 2016. On a conference call with investors and analysists, Defendant
Barrett stated that the “integration of Cordis has gone well and is on target.”
Defendant Kaufmann stated that “Cordis is off to a good start, with all key
personnel in place, and day-to-day operations up and running.” (Id. ¶ 47.)

• February 10, 2016. Defendant Barrett spoke at an analyst conference and stated
in response to a question about Cordis: “We’re off to a very good start. As we said
at the end of our second quarter, things are going as expected.” (Id. ¶ 49.)

• March 7, 2016. Defendant Barrett stated at an investor conference: “Again, for us
the Cordis acquisition, which is very early on and going well thus far”; and “Cordis
is off to a very good start, and nothing I’ve seen makes me less enthusiastic about
this part of the strategy.” (Id.)

• April 28, 2016. Defendant Barrett spoke on an earnings conference call that the
Cordis integration “remains on track.” Defendant Kauffmann stated: “the
onboarding of Cordis continues to progress well. We have filled the key roles with
excellent talent and are focused on execution”; and “I think it’s really important to
know that the underlying Cordis business is doing really well—done an excellent
job of staffing up, both from management and the sales teams.” (Id. ¶ 50.)

• June 15, 2016. Defendant Barrett remarked that “operationally the [Cordis]
integration is going extremely well. Market share is going well, we have retained
the talent we want, we have attracted additional talent on a global basis, we are
actually about where we modeled it . . . .” (Id. ¶ 51.)

• August 2, 2016. Defendant Barrett stated on an earning conference call that
Defendant Casey “and his team did a tremendous job closing the Cordis acquisition
on time and managing the integration into Cardinal Health . . . and we hit our
integration and performance benchmarks.” Defendant Kaufmann stated, “We think
things are going really well. We’ve got all of the key employees, management
teams, sales folks in place, things are going incredibly well.” (Id. ¶ 54.)

All of these statements about Cardinal’s integration efforts being “on track” and “as
planned” and “as expected” convey that the current state of the integration efforts had progressed
to a point that made it reasonably likely for Cardinal to complete the integration process by a
certain time. See Silverman v. Motorola, Inc., 2008 WL 4360648, at *10 (N.D. Ill. Sept. 23,
2008) (treating language about the company being “on track” as “statements of present fact that
could be considered material”). In re Akorn, Inc. Securities Litig., 240 F. Supp. 3d 802, 817
(N.D. Ill. 2017) (same?). Further, the veracity of these statements could have been determined at
the time they were made: “integration of Cordis has gone well and is on target,” that Cardinal has
“all key personnel in place, and day-to-day operations up and running,” it has in place “the key

roles with excellent talent,” “an excellent job of staffing up, both from management and the sales
teams,” “we hit our integration and performance benchmarks.” Consequently, these statements
fall outside of the safe harbor of the PSLRA.
c. Accurate statements of historical results

Defendants challenge statements they made in February, August and September 2017,
that they contend are not actionable as a matter of law. Specifically, Defendants assert:
The complaint also alleges that statements by the company and executives
disclosing the past performance of Cardinal Health and of Cordis on quarterly
earnings calls, and the reasons for that past performance, contained material
omissions. See, e.g., Am. Compl. ¶¶ 60-61, 68-73. According to the complaint,
such statements were materially incomplete because they were unaccompanied by
disclosures of alleged inventory problems that could hamper Cordis’ performance
in the future. See, e.g., id. ¶¶ 67, 71, 73, 83.)

(Defs’ Mot. at 19, ECF No. 31.)

Defendants contend:

As a matter of law, such allegations are inadequate to plead a material omission.
As the Sixth Circuit has explained: “It is clear that a violation of federal securities
law cannot be premised upon a company’s disclosure of accurate historical data.
The disclosure of accurate historical data does not become misleading even if less
favorable results might be predictable by the company in the future.” In re Sofamor
Danek Grp., Inc., 123 F.3d 394, 401 n.3 (6th Cir. 1997). Thus, the Sixth Circuit
held that the Ford company’s disclosure of historically accurate sales data for a
product was not rendered materially misleading by the omission of an
accompanying disclosure that the product was defective and that “the eventual
public revelation of the defect would affect adversely Ford’s financial status.” Ford,
381 F.3d at 570 (citing Sofamor, 123 F.3d at 401 n.3).

Id. Defendants’ arguments are not well taken.
This is not a situation, as Defendants argue, where there was a disclosure of accurate
historical data that Plaintiff alleges became misleading because less favorable results might be
predictable by the company in the future or an eventual public revelation that would adversely
effect Cardinal’s financial status. (Defs’ Mot. at 19) (quoted above). Instead, as the Sixth

Circuit explained, if a company chooses to volunteer information its “disclosure must be full and
fair, and courts may conclude that the company was obliged to disclose additional material facts .
. . to the extent that the volunteered disclosure was misleading . . . .” City of Monroe Employees
Ret. System v. Bridgestone Corp., 399 F.3d 651, 670 (6th Cir. 2005) (internal quotations
omitted). The court noted that “[o]ur securities laws therefore ‘require an actor to provide
complete and non-misleading information with respect to the subjects on which he undertakes to
speak.’” Id. (citations omitted). The Bridgestone Corporation court concluded:
The question thus is not whether a [defendant’s] silence can give rise to liability,
but whether liability may flow from his decision to speak . . . concerning material
details . . . , without revealing certain additional known facts necessary to make his
statements not misleading. This question is answered by the text of [SEC] Rule
10b–5(b) itself: it is unlawful for any person to “omit to state a material fact
necessary in order to make the statements made, in the light of the circumstances
under which they were made, not misleading . . . .”

Id. (citing, inter alia, 17 C.F.R. § 240.10b–5(b)).
With these standards in mind, the Court finds that the allegations at issue are not as a
matter of law inadequate to plead a material omission.
d. Conclusion of Material Misrepresentation
Examining Defendants’ statements in the context in which they were made, and as
alleged by Plaintiff, reasonable minds could infer that the statements made about the Cordis
integration were materially misleading because Defendants failed to disclose “known facts
necessary to make” the “statements not misleading.” City of Monroe, 399 F.3d at 670 (citation
omitted). Thus, the Court concludes that the alleged misrepresentations or omissions are not so
obviously unimportant to a reasonable investor “that reasonable minds cannot differ on the
question of materiality.” In re Cardinal Health Inc. Sec. Litigations, 426 F. Supp. 2d at 747.
Consequently, Plaintiff has sufficiently pleaded that the statements by Cardinal or its executives

regarding Cordis, or the company’s financial statements, contained material misrepresentations
or omissions.
2. Scienter

The PSLRA requires a plaintiff to “‘state with particularity facts giving rise to a strong
inference that the defendant acted with the required state of mind’” in making isrepresentations.
Frank v. Dana Corp., 646 F.3d 954, 958 (6th Cir. 2011) (quoting 15 U.S.C. §78u-4(b)(2)). In a
securities fraud case, “scienter includes a knowing and deliberate intent to manipulate, deceive,
or defraud, and recklessness.” Doshi v. Gen. Cable Corp., 823 F.3d 1032, 1039 (6th Cir. 2016)
(citations and internal quotations omitted). “Recklessness is defined as highly unreasonable
conduct which is an extreme departure from the standards of ordinary care’”—“akin to conscious
disregard.” Frank v. Dana Corp., 646 F.3d 954, 959 (6th Cir. 2011) (internal quotations and
citation omitted).
The Supreme Court has established a three-part test to determine whether a plaintiff’s
scienter allegations are sufficiently pleaded. Tellabs, 551 U.S. at 322–24.
“First, all of the plaintiff's factual allegations must be accepted as true.

Second, the complaint and other sources normally considered by a court when
ruling on a 12(b)(6) motion must be considered in their entirety, including
documents incorporated into the complaint by reference, and matters of which a
court may take judicial notice. The inquiry . . . is whether all of the facts alleged,
taken collectively, give rise to a strong inference of scienter, not whether any
individual allegation, scrutinized in isolation, meets that standard.
Third, the court must take into account plausible opposing inferences when
determining whether there is a strong inference of scienter. A complaint will
survive . . . only if a reasonable person would deem the inference of scienter cogent
and at least as compelling as any opposing inference one could draw from the facts
alleged.”

Frank v. Dana Corp., 646 F.3d 954, 959 (6th Cir. 2011) (citing Tellabs, 551 U.S. at 322–25)
(internal quotations and citations omitted). The Sixth Circuit applies this test with reference to
nine non-exhaustive “Helwig factors”:
(1) insider trading at a suspicious time or in an unusual amount;

(2) divergence between internal reports and external statements on the same subject;

(3) closeness in time of an allegedly fraudulent statement or omission and the later
disclosure of inconsistent information;

(4) evidence of bribery by a top company official;

(5) existence of an ancillary lawsuit charging fraud by a company and the company’s
quick settlement of that suit;

(6) disregard of the most current factual information before making statements;

(7) disclosure of accounting information in such a way that its negative implications
could only be understood by someone with a high degree of sophistication;

(8) the personal interest of certain directors in not informing disinterested directors of
an impending sale of stock; and

(9) the self-interested motivation of defendants in the form of saving their salaries or
jobs.

In re Omnicare, Inc. Sec. Litig., 769 F.3d 455, 473 (6th Cir. 2014) (citing Helwig, 251 F.3d at
552). The ultimate question is whether the allegations, viewed holistically and not piecemeal,
give rise to the “inference of scienter and at least as compelling as any opposing inference one
could draw from the facts alleged.” Tellabs, 551 U.S. at 324. “Whether [Plaintiff] can
ultimately prove [its] allegations and establish scienter is an altogether different question.”
Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27, 49 (2011).
Defendants argue that Plaintiff’s allegations fail to give rise to a strong inference of
scienter as required by the PSLRA. In response, Plaintiff contends that Defendants scrutinize
certain allegations such as their own insider sales and compensation, to argue that each, standing
alone, does not support an inference of scienter. Plaintiff maintains that, all facts probative of

scienter, however, must be considered collectively in assessing whether the Complaint raises a
strong inference, and here that consideration provides a strong inference of knowing or reckless
misconduct on the part of each defendant. (Pl’s Mem. in Opp. at 30) (citing Dana I, 547 F. 3d at
571). Plaintiff submits that the following facts, including four of the Helwig factors, collectively
raise a strong inference of knowing or reckless misconduct on the part of each defendant:
• insider trading by defendants Barrett and Casey in unusual amounts totaling
almost $114 million and at suspicious times;

• key executive departures of Defendants who were directly responsible for
the Cordis acquisition and integration, and who spoke positively about it to
investors: Wilson, Cordis’ president, in August 2017; Barrett, Cardinal’s
CEO, in January 2018; and Casey, CEO of Cardinal’s Medical Segment
who led the integration of Cordis, in February 2018;

• closeness in time of Defendants’ final Class Period misrepresentations
about Cordis on March 8, 2018 and their May 3, 2018 disclosures of
inconsistent information which shocked investors;

• the magnitude of the post-Class Period impact from Cardinal’s acquisition
of Cordis and the inventory and other problems Defendants concealed from
investors: Cardinal wrote down $1.4 billion in goodwill and tangible assets
– 74% of the price it paid for Cordis – causing a 94% decline in operating
profits, and doubled its year-over-year inventory reserves from $76 million
to $147 million;

• the importance of Cordis to Cardinal’s core business; and

• the self-interested motivations of Defendants to protect their performance-
based compensation.

(Pl. Mem. in Opp. at 30–31.) This Court agrees.
Throughout their motion and reply brief, Defendants present law that supports their
conclusions from inferences drawn in their favor from the facts and circumstances alleged. For
example, Defendants contend: “The fact that the negative statements were made throughout the
Class Period suggests an inference of honest and frank behavior on the part of Defendants, as

opposed to an intent to commit fraud and a scheme to inflate the stock price.” (Reply at 12, ECF
No. 36.) However, in evaluating the sufficiency of scienter allegations, the Supreme Court has
directed courts to “accept all factual allegations in the complaint as true,” view the allegations
“holistically” and consider whether “a reasonable person would deem the inference of scienter
cogent and at least as compelling as any opposing inference one could draw from the facts
alleged.” Tellabs, 551 U.S. at 322–26. “The inquiry is whether all of the facts alleged, taken
collectively, give rise to a strong inference of scienter, not whether any individual allegation,
scrutinized in isolation, meets the requisite standard.” Id. at 310. “[W]here two equally
compelling inferences can be drawn, one demonstrating scienter and the other supporting a
nonculpable explanation, Tellabs instructs that the complaint should be permitted to move

forward.” Dana I, 547 F. 3d at 571. In other words, Tellabs “‘awards the draw to the plaintiff.’”
Id.
In the instant action, it is alleged that Defendants continued to represent that the Cordis
acquisition and integration of inventory oversight with Cardinal’s systems was on track and
going well when internal reports showed that Cardinal knew that there were hundreds of millions
of dollars in obsolete inventory and there was an internal “dark period” where Defendants could
not track any Cordis inventory for approximately a year. Plaintiff’s allegations sufficiently show
that Defendants were aware of this. Viewed holistically, Plaintiff’s allegations give rise to the
strong inference of scienter required by Tellabs. That is, there is a strong inference of scienter
that may be drawn from these facts and circumstances that is at least as plausible as any non-
culpable inference suggested by Defendants.
3. Loss Causation
“In any private action arising under this chapter, the plaintiff shall have the burden of

proving that the act or omission of the defendant alleged to violate this chapter caused the loss
for which the plaintiff seeks to recover damages.” 15 U.S.C. § 78u-4(b)(4). At the pleading
stage, “a plaintiff need only ‘provide a defendant with some indication of the loss and the causal
connection that the plaintiff has in mind.’” Norfolk Cty. Ret. Sys. v. Cmty. Health Sys., Inc., 877
F.3d 687, 695 (6th Cir. 2017) (citing Dura Pharm., Inc. v. Broudo, 544 U.S. 336, 347, (2005));
see also In re Cardinal Health Inc. Securities Litigation, 426 F. Supp. 2d 688, 758 (S.D. Ohio
2006) (stating “[e]ssentially, a plaintiff needs to allege a drop in stock price; establish a causal
connection; and connect the alleged fraud with the ultimate disclosure and loss”). Plaintiff has
met that burden.
Plaintiff alleged a causal connection between Defendants’ alleged misleading statements

and omissions inflating Cardinal’s stock price and the stock price declines when negative
material information related to the statements and omissions was disclosed. (Am. Compl. ¶¶
131–137, ECF No. 28.) Specifically, the Amended Complaint contains the following
allegations: (a) Defendants misled investors by concealing Cordis’ debilitating inventory
management and tracking problems, that Cordis was carrying millions in excess, obsolete and
expired inventory not reflected in Cardinal’s publicly reported earnings, the cost overruns to set
up a global supply chain, and the fact that sales were being impacted by persistent back-order
issues (Id. ¶¶ 67, 71, 83, 92–103); (b) Defendants’ materially misleading statements and
omissions caused Cardinal’s stock price to trade at artificially inflated levels (Id. ¶ 131); (c)
Plaintiff and the Class purchased Cardinal stock at these inflated prices (id.); (d) on August 2,
2017, when Cardinal reported weak earnings for its 4Q and FY 2017 and lowered earnings
guidance for FY 2018 due to lost sales and cost issues at Cordis, including “higher-than-planned
write-offs for excess inventory,” Cardinal’s’ stock price dropped 8% (Id. ¶¶ 68–69, 133); (e) on

May 3, 2018, when Cardinal announced lower-than-expected earnings for 3Q 2018 due to
Cordis’ poor performance, which included an inventory reserve increase, and that as a result the
Company was reducing expected earnings for 2018 and that Cordis would not be profitable until
the end of 2019, Cardinal’s stock price dropped over 21% on unusually high trading volume (Id.
¶¶ 84–88, 134–136); and (f) as a direct result, Plaintiff and the Class suffered damages (Id. ¶
137).
These allegations are more than sufficient to plead the required “causal connection”
between Cardinal’s allegedly false and misleading financial statements and Plaintiff’s economic
loss.
B Claims Under §§ 20(a) and 20A

Plaintiff’s claims brought under § 10(b) and Rule 10b-5 of the Securities Exchange Act
require a predicate violation. Ross v. Abercrombie & Fitch Co., 501 F. Supp. 2d 1102, 1120
(S.D. Ohio 2007); PR Diamonds, Inc. v. Chandler, 364 F.3d 671, 696 (6th Cir. 2004). Because
the Court has not dismissed Plaintiff’s claims under § 10(b) and Rule 10b–5, the Defendants’
motion to dismiss the § 20(a) claim is not well taken.
IV.
Plaintiff also filed a Motion to Strike Exhibits Submitted with Defendants’ Motion to
Dismiss, which is fully briefed. (ECF Nos. 33, 37, 38.) The Court, however, need not make a
determination of this issue because even when considering the exhibits as part of the pleadings
and accepting them as the support Defendants intended them to be, Defendants’ Motion to
Dismiss was denied. Therefore, the Court finds that Plaintiff’s Motion has been rendered moot.
(ECF No. 33.)
V.

For the reasons stated above, the Court DENIES Defendants’ Motion to Dismiss (ECF
No. 31) and DENIES AS MOOT Plaintiff’s Motion to Strike Exhibits (ECF No. 33). This case
remains open on this Court’s docket.
IT IS SO ORDERED.
9/27/2021 s/Edmund A. Sargus, Jr.
DATE EDMUND A. SARGUS, JR.
UNITED STATES DISTRICT JUDGE

---

Source: Frix Law Library, https://www.frixlaw.com/law-library/cases/10378697. Public record. Not legal advice.